Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
03 déc. 2024 07h00 HE
|
Roivant Sciences
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and...
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
03 déc. 2024 07h00 HE
|
Roivant Sciences
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON...
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
12 nov. 2024 07h00 HE
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
29 oct. 2024 16h35 HE
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday,...
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
28 oct. 2024 09h25 HE
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives,...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
18 sept. 2024 07h30 HE
|
Roivant Sciences
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed...
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
10 sept. 2024 06h30 HE
|
Roivant Sciences
Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
10 sept. 2024 06h30 HE
|
Roivant Sciences
Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for...
Roivant Provides Update on Graves’ Disease Development Program
09 sept. 2024 07h00 HE
|
Roivant Sciences
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs...
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
08 août 2024 07h00 HE
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided a...